NAKI Therapeutics

NAKI Therapeutics is a private, research-focused biopharmaceutical company developing allogeneic, off-the-shelf CAR-NK cell therapies for oncology. The company's lead scientific focus is a CD147-targeted CAR-NK approach intended initially for hepatocellular carcinoma and potentially other solid tumors. NAKI also emphasizes a proprietary NK-cell expansion system designed to generate memory-like, highly potent NK and CAR-NK cells with improved persistence and scalability. Based on its public materials, the company appears to be at the preclinical stage, with published translational work supporting its platform and target selection. NAKI positions its programs around the promise of lower-toxicity cell therapy and more manufacturable off-the-shelf products relative to traditional autologous approaches.